In ovarian cancer SOX2 ectopic overexpression promotes tumor cell resistance to several chemotherapeutic compounds, such as cisplatin, carboplatin, and paclitaxel, by altering the homeostasis between pro- and anti-apoptotic proteins. Here, SOX2 is linked to ovarian cancer.